Several clinical trials have been conducted to evaluate the safety, tolerability, and efficacy of IPX-551 in patients with various diseases. These studies have provided valuable insights into the pharmacokinetics and pharmacodynamics of IPX-551, as well as its potential therapeutic applications.

Despite this promise, prior photonic‑receiver demonstrations have been limited by , high optical‑pump power , or inadequate integration of digital conversion [5,6]. The IPX‑551 project was conceived to address these gaps by integrating silicon‑nitride waveguide photonics , a low‑Vπ electro‑optic phase modulator , and a balanced germanium photodiode pair , all fabricated on a 200‑mm CMOS‑compatible platform. The resulting architecture delivers a compact, low‑power, high‑dynamic‑range front‑end suitable for mass production.

While the IPX-551 waterproofing standard offers several benefits, there are also some challenges and limitations associated with it. Some of the key challenges and limitations include:

[ \mathrmNF= \mathrmNF_LNA + \frac\mathrmNF_MZMG_\mathrmLNA + \frac\mathrmNF_PDG_\mathrmLNAG_\mathrmMZM ]